Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$10.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ellex Medical Lasers Ltd Announces Release of Positive Pilot Study Results for 2RT Treatment of Early AMD


Sunday, 13 Oct 2013 06:50pm EDT 

Ellex Medical Lasers Ltd announced that the results of a pilot study to investigate the efficacy of the Company’s Retinal Rejuvenation Therapy (2RT) in the treatment of early Age-Related Macular Degeneration (AMD) have been released and published in the peer-reviewed, scientific publication Clinical & Experimental Ophthalmology. 50 patients with bilateral at risk intermediate AMD were enrolled in the study with a 12-month followup period. Drusen are the accumulation of waste deposits in the macula and are a key risk factor to progression to end-stage, blinding AMD. These drusen were reduced in 44% of treated eyes. Of the 11 patients at greatest risk of disease progression (flicker defect >15dB), seven improved sufficiently to be taken out of this high-risk category. According to Tom Spurling, the publication of the results is a major milestone in the Company’s clinical investigations: “The study concluded that the application of 2RT produced improvements in macula function and appearance amongst the patient cohort and that as such it warrants ongoing evaluation as an early intervention for AMD.” Until now, treatment options have been restricted to targeting late-stage complications associated with the wet form of AMD, which only accounts for 10-15% of all people who suffer from AMD. 

Company Quote

0.32
 --
27 Nov 2014